Walleye Trading’s ARS Pharmaceuticals SPRY Stock Holding History

Walleye Trading’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-18,956	Closed	-$189K	–	5831
2021 Q3	$189K	Buy	+18,956	New	+$467K	﹤0.01%	3911

Other funds holding SPRY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Walleye Trading's SPRY Position: Q4 2021 in Review

Walleye Trading sold out of ARS Pharmaceuticals (SPRY) in Q4 2021, closing a stake of 18,956 shares — an estimated $189K sold.

Walleye Trading first reported a position in SPRY in Q3 2021 and held it in 1 quarter. The position peaked at $189K in Q3 2021. 72 funds tracked by Wall St. Rank hold SPRY as of Q4 2021.

Walleye Trading reported no remaining ARS Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Walleye Trading sold 18,956 ARS Pharmaceuticals shares in Q4 2021, an estimated $189K.
Walleye Trading first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Walleye Trading's ARS Pharmaceuticals position peaked at $189K in Q3 2021.
72 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.